Wall Street brokerages expect that Fennec Pharmaceuticals Inc (NASDAQ:FENC) will report earnings per share (EPS) of ($0.15) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Fennec Pharmaceuticals’ earnings. Fennec Pharmaceuticals reported earnings per share of ($0.08) during the same quarter last year, which suggests a negative year over year growth rate of 87.5%. The business is expected to issue its next earnings report on Thursday, March 29th.
On average, analysts expect that Fennec Pharmaceuticals will report full-year earnings of ($0.48) per share for the current year. For the next year, analysts anticipate that the business will post earnings of ($0.45) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Fennec Pharmaceuticals.
Several equities analysts have recently issued reports on FENC shares. Wedbush started coverage on Fennec Pharmaceuticals in a report on Monday. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright started coverage on Fennec Pharmaceuticals in a report on Tuesday, February 20th. They issued a “buy” rating and a $16.00 price objective for the company. ValuEngine raised Fennec Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Laidlaw started coverage on Fennec Pharmaceuticals in a report on Wednesday, November 29th. They issued a “buy” rating and a $22.00 price objective for the company.
Shares of Fennec Pharmaceuticals (NASDAQ FENC) traded up $0.06 during mid-day trading on Friday, hitting $9.43. The stock had a trading volume of 68,977 shares, compared to its average volume of 27,870. The firm has a market cap of $173.62, a PE ratio of -23.58 and a beta of 0.44. Fennec Pharmaceuticals has a fifty-two week low of $2.30 and a fifty-two week high of $13.95.
Several hedge funds have recently modified their holdings of the company. 683 Capital Management LLC lifted its holdings in shares of Fennec Pharmaceuticals by 7.3% in the 4th quarter. 683 Capital Management LLC now owns 867,185 shares of the company’s stock valued at $8,689,000 after buying an additional 58,820 shares during the period. Opaleye Management Inc. acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at about $8,486,000. Finally, Cardinal Capital Management acquired a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at about $120,000. 44.94% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Brokerages Expect Fennec Pharmaceuticals Inc (FENC) Will Post Earnings of -$0.15 Per Share” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/14/brokerages-expect-fennec-pharmaceuticals-inc-fenc-will-post-earnings-of-0-15-per-share.html.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, formerly Adherex Technologies Inc, is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.